An interventional study of Galactooligosaccharides (GOS) in Resistance Exercise, sponsored by North-West University, South Africa. Completed at 1 site in South Africa. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by North-West University, South Africa · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Inflammation with a site in South Africa — 3 open to participants now, 4 under way, 1 of them phase 3. Inflammation · South Africa.
Among the 14 studies in Inflammation with a site in South Africa, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 with no phase, and was the 12th registered.
3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.
Browse Inflammation studies →3 of the 14 studies in Inflammation with a site in South Africa are open now. Recruiting first, the newest first:
Linda Malan · Sites in South Africa
Ages 18–35 · Women only · Healthy volunteers
Novartis Pharmaceuticals · Sites in South Africa, United States, Belgium and 19 more countries
Ages 6–100
University of Cape Town · Sites in South Africa
Ages 18–65
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.
This study: 18 Years to 35 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 50 across 2,586 interventional studies indexed under Inflammation.
Median enrollment 220 across the 13 interventional studies, 1,025 across the 1 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 10 most frequent:
North-West University, South Africa is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
North-West University, South Africa has 1 study filed under Inflammation — fewer than ten, so there is no comparison to draw.
1 of the studies in Inflammation with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07081152Linda MalanIron Absorption and Losses in Young South African Women Living Without and With Overweight and Obesity | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Inflammation with a site in South Africa, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Iron depletion is common in female athletes depending on the sports discipline. Endurance and resistance exercise can induce inflammation thereby reducing dietary iron absorption. Galacto-oligosaccharides (GOS) improved iron absorption in young healthy women and infants, and improved gut inflammation in iron-supplemented infants. A stable isotope study will be performed to investigate the effect exercise and acute and chronic GOS supplementation on inflammation and iron absorption in female athletes.
Iron depletion is common in athletes, particularly in females, reaching prevalence rates up to 70% depending on the sports discipline. As iron is essential for energy production and oxygen transport, a deficiency can impair performance, especially in endurance athletes. Iron deficiency in athletes may be caused by inadequate intake, but reduced iron absorption and increased losses also seem to play a role. Both endurance and resistance exercise at a high intensity, can induce inflammation resulting in a hepcidin response via interleukin-6 (IL-6) regulation. Hepcidin is the master regulator of systemic iron homeostasis, and a recent study in adult males showed that vigorous exercise decreases dietary iron absorption associated with increases in IL-6 and hepcidin. Iron losses induced by exercise have been attributed to several factors, including gastrointestinal bleeding associated with endothelial damage, haematuria, haemolysis, and increased sweating. Galacto-oligosaccharides (GOS) have been shown to acutely enhance iron absorption in young, healthy women. In Kenyan infants with a high infectious disease burden, chronic GOS administration improved iron absorption and mitigated the negative effects of iron supplementation on gut inflammation, likely mediated by its bifidogenic effect. Whether GOS has the potential of improving iron absorption has not been studied in athletes.
The study aims are to determine 1) the effects of a bout of resistance exercise at 70% 1 repetition maximum (RM) on inflammation, hepcidin and iron absorption in female team athletes; and 2) the effect of acute and chronic GOS supplementation on iron absorption in response to the exercise bout.
The trial will entail two series of three iron absorption conditions separated by six weeks of GOS supplementation (10 g/day). The study participants will be 22 female athletes recruited from the North-West University and Potchefstroom area, South Africa. At baseline, the first series of three iron absorption studies will be conducted, all measuring iron absorption from a supplement administered with labelled ferrous fumarate in the following conditions: 1) after a period of rest; 2) three hours after an acute resistance exercise bout; and 3) three hours after an acute resistance exercise bout, co-administered with GOS. Following this, participants will consume GOS daily for 6 weeks, followed by an identical series of iron absorption studies. Markers of systemic and gut inflammation, hepcidin, microflora composition and iron status indicators before and after the GOS intervention will be determined. In addition, erythrocyte iron incorporation will be determined after both series of isotope studies. Furthermore, the kinetics of isotope appearance, inflammatory markers, and hepcidin for 24 hours during each of the six iron absorption studies will be investigated.
The primary hypotheses are that fractional iron absorption from a supplemental dose of ferrous fumarate will be: 1) lower three hours post exercise than post resting period; 2) higher with co-administration of GOS than without, both before and after six-week GOS intervention; and 3) higher after six-week intervention with GOS compared to baseline.
The secondary hypotheses are: 1) acute exercise bout will result in increased inflammatory and hepcidin response before and after intervention with GOS but the intervention may mediate these two responses; 2) chronic GOS intervention will increase relative abundance of Bifidobacterium spp, reduce gut inflammation and improve gut integrity and gut health; 3) chronic GOS intervention will improve iron status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 10 g of GOS daily for 6 weeks. Fractional iron absorption will be determined pre- and post the 6-week intervention from 3 conditions: 1) after a period of rest; 2) three hours after an acute resistance exercise bout without GOS and 3) three hours after an acute resistance exercise bout, co-administered with 10 g GOS.
Dietary Supplement: Galactooligosaccharides (GOS)
10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt. The absorption study test drinks administered during the 3 test conditions will be comprised as follows: Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose. Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose. Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS.
a. Fractional iron absorption (%)
Fractional iron absorption will be measured at rest and after an exercise bout.
Time frame: Visit 8 (day 29) and 15 (day 92).
b. Fractional iron absorption (%)
Fractional iron absorption will be measured after an exercise bout with and without co-administration of GOS.
Time frame: Visit 8 (day 29) and 15 (day 92).
c. Fractional iron absorption (%)
Fractional iron absorption will be measured at rest and after an exercise bout before and after a 6-week intervention with GOS.
Time frame: Visit 8 (day 29) and 15 (day 92).
Interleukin 6 (pg/mL)
Interleukin 6 (IL-6) will be measured over 24 hours after rest and after exercise as a marker of exercise-induced inflammation.
Time frame: Visits 2 (day 1), 3 (day 2), 4 (day 8), 5 (day 9), 6 (day 15), 7 (day 16), 9 (day 64), 10 (day 65), 11 (day 71), 12 (day 72), 13 (day 78) and 14 (day 79)
C-reactive protein (mg/L)
C-reactive protein (CRP) will be measured in plasma to detect the presence of acute inflammation.
Time frame: Visits 2 (day 1), 4 (day 8), 6 (day 15), 9 (day 64), 11 (day 71) and 13 (day 78).
Alpha-1-acid glycoprotein (g/L)
Alpha-1-acid glycoprotein (AGP) will be measured in plasma to determine the presence of chronic inflammation.
Time frame: Visits 2 (day 1), 4 (day 8), 6 (day 15), 9 (day 64), 11 (day 71) and 13 (day 78).
Hepcidin (ng/mL)
Hepcidin, a major regulator of iron absorption and influenced by exercise-induced inflammation, will be measured in plasma over 24 hours.
Time frame: Visits 2 (day 1), 3 (day 2), 4 (day 8), 5 (day 9), 6 (day 15), 7 (day 16), 9 (day 64), 10 (day 65), 11 (day 71), 12 (day 72), 13 (day 78) and 14 (day 79)
Lipid mediators (pg/µL )
The following lipid mediators will be measured over 24 hours in plasma in response to exercise-induced inflammation:17-hydroxydocosahexaenoicacid (17-HDHA); 5-, 8-, 9-, 11-, 12-, 15 and 18- hydroxyeicosapentaenoicacid (HEPE); 5-, 8-, 11-, 12- and 15-hydroxyeicosatetraenoicacid (HETE); prostaglandin (PG) E2 and D2, and resolvin (Rv) D1 and E1).
Time frame: Visits 2 (day 1), 3 (day 2), 4 (day 8), 5 (day 9), 6 (day 15), 7 (day 16), 9 (day 64), 10 (day 65), 11 (day 71), 12 (day 72), 13 (day 78) and 14 (day 79)
Erythropoietin (mIU/mL)
Plasma erythropoietin, a marker of erythropoiesis, will be measured before and after period of rest and exercise.
Time frame: Visits 2 (day 1), 4 (day 8), 6 (day 15), 9 (day 64), 11 (day 71) and 13 (day 78).
Serum iron isotope (%)
Kinetics of serum iron isotope appearance during a period of rest and post-exercise, before and after intervention with GOS, and with and without co-administration of GOS.
Time frame: Visits 2 (day 1), 3 (day 2), 4 (day 8), 5 (day 9), 6 (day 15), 7 (day 16), 9 (day 64), 10 (day 65), 11 (day 71), 12 (day 72), 13 (day 78) and 14 (day 79).
Gut microbial composition
Gut microbiota profile will be assessed at baseline and endpoint.
Time frame: Visit 8 (day 29) and 15 (day 92).
Faecal short chain fatty acids (µmol/g)
Concentration of short chain fatty acids - acetate, propionate, isobutyrate, butyrate, formate, isovalerate will be measured in faecal samples before and after the 6-week intervention with GOS.
Time frame: Visit 8 (day 29) and 15 (day 92).
Faecal pH
Faecal pH will be measured at baseline and endpoint to determine a response to the GOS intervention.
Time frame: Visit 8 (day 29) and 15 (day 92).
Faecal calprotectin (µg/g)
Faecal calprotectin will be measured at baseline and endpoint as a marker of gut inflammation.
Time frame: Visit 8 (day 29) and 15 (day 92).
Faecal zonulin (ng/mL)
Faecal zonulin will be measured at baseline and endpoint as a marker of the integrity of the intestinal mucosal barrier.
Time frame: Visit 8 (day 29) and 15 (day 92).
Intestinal fatty acid-binding protein (pg/mL)
Intestinal fatty acid-binding protein (I-FABP), a marker of intestinal damage, will be measured in plasma at baseline and endpoint.
Time frame: Screening, Visits 4 (day 8), 8 (day 29), 9 (day 64), 11 (day 71) and 15 (day 92).
Haemoglobin (g/dL)
Haemoglobin will be measured in whole blood to determine presence of anaemia and for calculation of fractional iron absorption.
Time frame: Screening,Visit 8 (day 29), 9 (day 64) and 15 (day 92).
Ferritin (µg/L)
Ferritin will be measured in plasma to determine the presence of iron deficiency.
Time frame: Screening, Visits 2 (day 1) and 9 (day 64).
Soluble transferrin receptor (mg/L)
Soluble transferrin receptor (sTfR) will be measured in plasma to determine the presence of iron deficiency.
Time frame: Screening, Visits 2 (day 1) and 9 (day 64).
Retinol-binding protein 4 (µmol/L)
Retinol-binding protein 4 (RBP4) will be measured in plasma as a marker of vitamin A status.
Time frame: Screening, Visits 2 (day 1) and 9 (day 64).
Thyroglobulin (µg/L)
Thyroglobulin will be measured in plasma as a marker of iodine status.
Time frame: Screening, Visits 2 (day 1) and 9 (day 64).
Fibroblast growth factor 21 (pg/mL)
Fibroblast growth factor 21 (FGF-21) will be measured in plasma as a marker of environmental enteric dysfunction (EED).
Time frame: Screening,Visits 2 (day 1) and 9 (day 64).
Insulin-like growth factor 1
Insulin-like growth factor 1 (IGF-1) will be measured in plasma as on of the markers of environmental enteric dysfunction.
Time frame: Screening, Visits 2 (day 1) and 9 (day 64).
Dietary intake
Dietary intake will be captured using a quantified food frequency questionnaire.
Time frame: Screening, Visit 8 (day 29) and 15 (day 92).
Method comparison in the measurement of RBP4 (µmol/L)
Two methods will be compared in the measurement of RBP4 (µmol/L).
Time frame: Screening
Method comparison in the measurement of Ferritin (µg/L)
Two methods will be compared in the measurement of Ferritin (µg/L).
Time frame: Screening
Method comparison in the measurement of sTfR (mg/L)
Two methods will be compared in the measurement of sTfR (mg/L).
Time frame: Screening
Method comparison in the measurement of CRP (mg/L)
Two methods will be compared in the measurement of CRP (mg/L).
Time frame: Screening
Method comparison in the measurement of AGP (g/L)
Two methods will be compared in the measurement of AGP (g/L).
Time frame: Screening
Method comparison in the measurement of I-FABP (pg/mL)
Two methods will be compared in the measurement of I-FABP (pg/mL).
Time frame: Screening
Method comparison in the measurement of Thyroglobulin (µg/L)
Two methods will be compared in the measurement of Thyroglobulin (µg/L).
Time frame: Screening
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Nov 2024, 8 months.
Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 8 months is below that.
Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
North-West University, South Africa